Candel Therapeutics Falls to 52-Week Low After Interim CAN-2409 Study Data
By Josh Beckerman Shares of Candel Therapeutics fell to a 52-week low after the cancer-focused biopharmaceutical company reported interim data from a...
Stay updated with breaking news from Service Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Josh Beckerman Shares of Candel Therapeutics fell to a 52-week low after the cancer-focused biopharmaceutical company reported interim data from a...
By Ben Glickman TC BioPharm Holdings has reached a deal for Fortrea to manage its global clinical trials, the latest cost-cutting effort by the...
By Colin Kellaher Kronos Bio is shedding about 19% of its staff as the clinical-stage biopharmaceutical moves to extend its cash runway following positive...
By Stephen Nakrosis Nurix Therapeutics on Wednesday said the Food and Drug Administration placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study...
By Rob Curran Biotech company Mersana Therapeutics said the Food and Drug Administration lifted a clinical hold on a Phase 1 trial of one of its...